Hormonal Health and Its Role in Wellness With DHEA

Unlock the secrets to hormonal health and DHEA. Discover how to enhance your well-being with personalized interventions and insights.

Educational Abstract

In this educational post, I walk you through a practical, evidence-based roadmap for optimizing hormone health using an integrative model that aligns endocrine physiology, metabolic function, gut health, and individualized lifestyle interventions. Drawing on contemporary research and decades of clinical experience, I explain why patients can have “normal” lab values yet remain symptomatic, and how factors such as thyroid status, vitamin D, sex hormone–binding globulin (SHBG), insulin resistance, and gut dysbiosis modulate hormone signaling. I outline a stepwise approach to managing polycystic ovary syndrome (PCOS) with a gut-first, insulin-centered strategy, while integrating judicious use of anti-androgens, metformin or GLP-1/GIP agonists, and carefully dosed testosterone when indicated. I also detail best practices for prostate-specific antigen (PSA) and percent-free PSA in men on testosterone therapy, emphasizing the role of MRI in reducing unnecessary biopsies. Finally, I highlight the neurosteroid and immunomodulatory importance of dehydroepiandrosterone (DHEA), including dosing logic and clinical applications. Throughout, I connect the dots with integrative chiropractic care—structural, autonomic, and lifestyle interventions that complement endocrine treatment—to improve outcomes and durability of response.

About the author: Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

Hormone Optimization Through An Integrative Lens

I have spent years in family and functional practice asking a simple question: why do some patients achieve desirable serum hormone levels but continue to feel unwell? My answer is a map born from practice and research: harmonize the endocrine system with the metabolic, inflammatory, and autonomic systems; treat the gut as a primary endocrine organ; and integrate movement, structural care, and nutrition as co-therapies. This model consistently produces better symptom relief and long-term stability.

Key concepts covered in this post:

• The physiologic role of SHBG and why “lowering SHBG” is rarely the target
• Thyroid and vitamin D as hormone-sensitivity amplifiers
• Gut dysbiosis as a root driver of PCOS and insulin resistance
• Practical protocols for metformin and GLP-1/GIP agonists
• Strategic use of spironolactone for hirsutism/acne in PCOS
• How to titrate testosterone in insulin-resistant, PCOS-like phenotypes
• How and why to use PSA and percent-free PSA in men, and when MRI is the next step
• DHEA is a neurosteroid and immunomodulator with its own receptor activity
• Where integrative chiropractic care enhances endocrine outcomes

Why “Normal” Hormones Can Still Feel Wrong: Receptor BiologCofactorsors, and Systems Context

I learned early in my career that serum numbers alone don’t capture clinical reality. Hormone action depends on:

• Adequate receptor expression and sensitivity
• Cell membrane composition and transport mechanisms
• Cofactors like thyroid hormones and vitamin D that regulate gene transcription and receptor density
• Metabolic context (insulin, inflammation, oxidative stress)
• Clearance and conjugation pathways (liver, gut microbiome)

Vitamin D, for example, is not only a secosteroid; it modulates nuclear receptor co-activators and influences androgen receptor function and aromatase activity. I have seen patients with excellent testosterone concentrations report low energy and libido until we corrected profoundly low 25(OH)D; once vitamin D was normalized, their symptom trajectory improved markedly. This aligns with evidence linking vitamin D status to muscle function, immune tone, and sex steroid signaling (Pilz et al., 2011; Lerchbaum & Obermayer-Pietsch, 2012).

Similarly, suboptimal thyroid function blunts tissue-level responsiveness to androgens and estrogens. Thyroid hormones regulate mitochondrial biogenesis, beta-adrenergic sensitivity, and basal metabolic rate—prerequisites for translating hormone signals into felt vitality. When thyroid is low-normal or clinically hypothyroid, patients may have “adequate” testosterone but insufficient downstream action. Optimizing thyroid (when indicated) often unmasks the benefits of hormone therapy (Biondi, 2019).

Understanding SHBG: Signal Quality Over Serum Quantity

SHBG binds testosterone and estradiol with high affinity, serving as a dynamic buffer and transport protein. The impulse to “lower SHBG” to raise free testosterone is often misguided. Epidemiology and mechanistic studies link low SHBG to metabolic syndrome, insulin resistance, and increased cardiometabolic risk (Ding et al., 2009; Rosner et al., 2007). Conversely, high SHBG can reduce free testosterone, creating symptomatic patients despite normal total T.

Key points:

• Low SHBG is frequently a biomarker of insulin resistance and hepatic metabolic stress; further lowering it may increase risk.
• High SHBG is influenced by estrogen exposure, hyperthyroidism, low insulin, alcohol use, and certain medications (Simo et al., 2012).
• The clinical strategy is not to suppress SHBG but to:

• Optimize insulin sensitivity (diet, exercise, metformin, GLP-1/GIP agonists)
• Ensure adequate protein and micronutrients
• Adjust testosterone dosing to achieve symptom control while respecting safety markers
• Consider botanical and nutraceutical supports that improve androgen metabolism and hepatic function when appropriate

Why this matters: The free testosterone fraction responds to both SHBG and total testosterone. In thin patients or those with elevated SHBG (e.g., higher estradiol exposure, thyroid over-replacement), a small increase in testosterone, alongside lifestyle and metabolic optimizations, can restore free T to a symptomatic sweet spot without compromising SHBG’s protective metabolic role.

PCOS As A Gut–Metabolic–Endocrine Disorder

Modern research reframes PCOS not as a purely ovarian condition but as a systemic disorder rooted in insulin resistance, inflammation, and gut dysbiosis (Qi et al., 2022). Dysbiosis alters bile acid signaling, short-chain fatty acid profiles, and gut permeability, driving low-grade inflammation and hyperinsulinemia. Elevated insulin suppresses SHBG and increases ovarian theca cell androgen production, leading to hyperandrogenism, cycle dysregulation, and hirsutism/acne (Diamanti-Kandarakis & Dunaif, 2012).

Diagnostic anchors:

• Rotterdam criteria (two of three): oligo/anovulation, hyperandrogenism (clinical or biochemical), polycystic ovaries
• Insulin resistance often precedes overt hyperandrogenism
• LH: FSH ratio may be elevated in some patients, but it is not universally reliable

Why gut-first care: The microbiome modulates hepatic SHBG synthesis, insulin signaling, and estrogen recirculation via beta-glucuronidase. Addressing dysbiosis improves insulin sensitivity and reduces androgen excess.

My clinical approach for PCOS integrates:

• Gut care basics

• • Ensure regular bowel movements
  • Reduce ultra-processed food burden; emphasize whole foods, fiber, and polyphenols.s
  • Use a broad-spectrum, clinically validated probiotic when the diet change is initially limited.

• Insulin-centered therapy

• • Metformin with slow titration to 2000 mg/day as tolerated, or
  • GLP-1/GIP agonists (e.g., semaglutide, tirzepatide) in appropriate candidates for weight loss and insulin sensitivity

• Androgen symptom management

• Spironolactone for hirsutism/acne when indicated

• Thyroid and progesterone support

• • Many PCOS patients exhibit suboptimal thyroid function that blunts ovulatory recovery.y
  • Progesterone deficiency contributes to early miscarriage risk; judicious progesterone support can be pivotal for fertility.

Why each intervention:

• Metformin improves hepatic glucose output and increases peripheral insulin sensitivity, leading to increased SHBG synthesis and decreased free testosterone (Lord et al., 2003).
• GLP-1/GIP agonists reduce appetite, improve beta-cell function, and reduce systemic inflammation, thereby facilitating recovery of ovulation (Jensterle et al., 2015).
• Spironolactone blocks the androgen receptor and 5-alpha-reductase activity in skin, reducing hirsutism and acne over 6–12 months; it does not treat root causes and must be paired with metabolic and gut interventions (Brown et al., 2009).
• Probiotics and prebiotic fibers modulate endotoxemia and insulin signaling; early evidence supports improved metabolic markers in PCOS with targeted microbiome strategies (Rath et al., 2022).

Metformin Titration That Patients Can Tolerate

Gastrointestinal intolerance is the primary barrier to achieving an effective metformin dose. A “start low, go slow” approach works:

• Begin with 500 mg with the evening meal
• After 1–2 weeks, add 500 mg with breakfast
• Progress to extended release as needed, aiming for 1000 mg twice daily
• Pause escalation during GI flares; patience preserves adherence

This reduces GI adverse effects as gut receptors adapt. The metabolic payoff—lower insulin, higher SHBG, lower free testosterone—generally emerges over weeks to months.

Spironolactone In PCOS: When and How

For PCOS patients with significant hirsutism/acne:

• Dose: often 100 mg/day in true PCOS patients (with monitoring for potassium and blood pressure)
• Mechanism: antagonizes the androgen receptor and reduces the DHT effect in the pilosebaceous unit
• Expect timeline: 6–12 months for maximal cosmetic benefit
• Contraception: necessary in those of reproductive potential, given the teratogenic risk to male fetuses
• In non-PCOS women with mild hair growth, I rarely exceed 50 mg/day to avoid over-suppressing androgen tone and libido

Hormone Therapy In Insulin-Resistant, PCOS-Like Phenotypes

If a woman presents insulin resistance with PCOS-like sensitivity and needs testosterone optimization (e.g., low libido, low energy), I  proceed cautiously:

• Start with low-dose testosterone (e.g., 50–87.5 mg if using pellets) and titrate slowly
• Rationale: lower SHBG and heightened follicular sensitivity can amplify androgenic side effects
• Build the foundation first: insulin control, gut health, thyroid, vitamin D, and progesterone support as indicated
• Monitor free testosterone and symptoms, not just total T

This “start low, go slow” strategy manages the risk of acne/hirsutism while allowing benefits in mood, libido, and energy to emerge.

Integrative Chiropractic Care: Enhancing Endocrine Outcomes

As a chiropractor and nurse practitioner, I see daily how structure and autonomic balance influence endocrine physiology. The spine and autonomic nervous system (ANS) regulate:

• Hypothalamic-pituitary-adrenal-gonadal (HPAG) axis tone via vagal and sympathetic inputs
• Motility and barrier function in the GI tract
• Sleep architecture and parasympathetic recovery—key for insulin sensitivity and hormone receptor expression

How chiropractic and integrative care fit:

• Targeted spinal manipulation can reduce nociceptive load, improving HRV and parasympathetic tone. Better vagal tone correlates with improved glycemic control and reduced systemic inflammation.
• Myofascial release and corrective exercise restore diaphragmatic mechanics, augmenting lymphatic and venous return, which aids cytokine clearance and sleep quality.
• Lifestyle coaching on circadian rhythm (light exposure, meal timing, and intermittent fasting) supports insulin signaling and leptin sensitivity.
• Movement prescriptions—progressive resistance training—enhance GLUT4 expression and SHBG levels by improving hepatic insulin sensitivity.

In my clinic, when we pair hormone therapy with structured movement therapy and manual care, patients report faster improvements in fatigue, sleep, and pain. Those changes often precede lab shifts, signaling improved receptor responsiveness and cellular energy levels.

PSA And Percent-Free PSA: Smarter Screening In Men On Testosterone

The field has matured in recognizing that testosterone therapy does not inherently cause prostate cancer, but vigilance is essential. Here is how I approach PSA:

• Baseline PSA before initiating testosterone therapy in men over 40–50 or with risk factors (AUA, 2023)
• Track not just absolute PSA, but:

• • Percent-free PSA: improved sensitivity for clinically significant prostate cancer when total PSA is in the gray zone (Catalona et al., 1998)
  • PSA velocity: a rapid rise (e.g., 0.9 to 2.9 ng/mL in one year) increases suspicion

• Practical lab setup:

• • Request auto-reflex percent-free PSA when total PSA exceeds the laboratory threshold (often 4.0 ng/mL, customizable with your lab)
  • Counsel patients to avoid ejaculation and vigorous cycling for 48 hours before PSA draws; note that such activities affect total PSA but not percent-free PSA

• Interpreting percent-free PSA:

• • Less than 10%: high likelihood of prostate cancer in the appropriate PSA range—refer or proceed to MRI
  • 10–25%: intermediate—consider prostatitis workup or MRI
  • GreMultiparametriclower likelihood—monitor

Why prostate MR Multi-parametric MRI has become the preferred noninvasive modality to localize suspicious lesions and reduce unnecessary biopsies (Ahmed et al., 2017)

• Radiologists can differentiate prostatitis/BPH patterns from suspicious lesions and provide PIRADS scoring to guide urology referral

Medication caveat:

• 5-alpha-reductase inhibitors (e.g., finasteride) reduce PSA by ~50%; double measured values to estimate baseline PSA during interpretation (Thompson et al., 2006)

When cancer has been treated and PSA normalizes, current guidance supports reinitiating testosterone in select men after shared decision-making and urology collaboration (AUA, 2018 update).

DHEA: The Underappreciated Neurosteroid And Immune Modulator

DHEA is not just a precursor to testosterone and estradiol. It is a potent neurosteroid with its own receptors and direct effects in the brain and immune system. Serum DHEA-S levels dwarf testosterone concentrations and decline steeply with age (Labrie et al., 2005).

Physiologic actions:

• Neuroprotection, mood, and cognitive support via GABAergic and glutamatergic modulation
• Immunomodulation, enhancing natural killer cell function and balancing Th1/Th2 responses
• Endothelial support and anti-atherosclerotic effects
• Bone density and muscle function support
• Counter-regulation of cortisol: chronic stress elevates cortisol while suppressing DHEA; restoring DHEA may help rebalance the stress axis

Clinical pattern I see:

• Patients—especially women—report lingering low mood, low libido, and joint aches despite optimized thyroid and sex steroids. Frequently, their DHEA-S is low relative to age and sex. Optimizing DHEA can be the missing piece that restores vitality and libido.

PCOS nuance:

• Some PCOS phenotypes display elevated DHEA-S from adrenal hyperandrogenism; in those cases, I avoid DHEA and focus on insulin control, stress modulation, and anti-androgen symptom management.

Dosing logic:

• Test DHEA-S (the stable sulfated form)
• Aim for the upper-normal range associated with better outcomes, individualized by sex and age (Traish et al., 2011)
• Compounded DHEA offers predictable dosing; typical starting doses:

• Women: 5–10 mg/day, titrate to 10–20 mg/day as needed and tolerated
• Men: 15–25 mg/day, titrate to 25–50 mg/day

• Monitor for androgenic side effects (acne, hair changes); in those prone to 5-alpha-reductase conversion, lower the dose or pair with lifestyle anti-inflammatory strategies.

Why it works for libido:

• DHEA serves as a substrate for local intracrine production of androgens in tissues and may enhance dopamine signaling linked to sexual desire. In contrast,e its conversion to DHT in limited local contexts can facilitate libido without requiring high systemic testosterone (Labrie, 2015).

Building The Foundation: Vitamin D, Thyroid, Nutrition, Sleep, Movement

I have repeatedly observed that without fundamentals, hormone therapy underperforms:

• Vitamin D: target 25(OH)D 40–60 ng/mL unless contraindicated
• Thyroid: treat true hypothyroidism and address suboptimal states when symptomatic with corroborating markers
• Nutrition: prioritize protein adequacy, omega-3s, polyphenols; reduce refined carbohydrates and industrial seed oils
• Sleep: 7–9 hours protects insulin sensitivity and GH/IGF-1 balance
• Exercise: resistance training and interval work increase GLUT4 translocation, improve hepatic insulin sensitivity, and raise SHBG
• Stress modulation: breathwork, HRV-guided training, and manual therapies to shift ANS toward parasympathetic dominance

Integrative Chiropractic Care Applied:

• Spinal manipulation to reduce segmental dysfunction and nociceptive drive that maintains sympathetic overactivation
• Diaphragmatic and rib cage mobility work to normalize vagal afferent signaling
• Corrective exercises to enhance posterior chain strength and glucose disposal
• Education around pacing and recovery to protect adrenal rhythm

Case-Informed Insights From My Clinic

• Vitamin D as a receptor: Patients with “good” testosterone numbers but persistent fatigue or low libido improved after we systematically corrected vitamin D deficiency, supporting its role in nuclear receptor co-activation and mitochondrial function.
• PCOS fertility trajectory: When we sequenced gut care, metformin/GLP-1 support, spironolactone for symptom relief, thyroid optimization, and robust progesterone support in early pregnancy attempts, ovulation patterns normalized over months, and sustainable pregnancies followed after 2–3 years of metabolic stabilization. The timeline is real; counseling patients about expectations sustains adherence.
• Testosterone in high-SHBG patients: We found that raising total testosterone modestly, while improving insulin sensitivity and maintaining healthy SHBG, yielded better symptom relief than aggressively pursuing lower SHBG. Side effects were fewer, and sleep tended to improve.
• DHEA as a”finisher”: In patients still struggling with mood and libido after core hormones were optimized, bringing DHEA-S into the upper-normal range often provided the final 20% improvement in quality of life.

Safety, Monitoring, And Shared Decision-Making

• Women on anti-androgens: monitor potassium and blood pressure with spironolactone; ensure contraception when appropriate.
• Metformin: monitor B12 annually; consider periodic lactate only if risk factors present; titrate slowly.
• GLP-1/GIP agonists: screen for personal/family history of medullary thyroid carcinoma or MEN2; monitor GI tolerance and glycemic response.
• Testosterone: track CBC (hematocrit), lipids, LFTs, and, in men, PSA with percent-free PSA; consider MRI if PSA/percent-free PSA patterns suggest risk.
• DHEA: recheck DHEA-S and clinical response in 8–12 weeks; adjust based on outcomes and side effects.

Putting It All Together: A Practical Flow

• Step 1: Assess the terrain

• • Symptoms, cycle history, sexual function, sleep, stress, diet, movement
  • Labs: CBC, CMP, lipid panel, A1c, fasting insulin, 25(OH)D, TSH/free T4 +/- free T3, ferritin, B12, SHBG, total and free testosterone, estradiol, progesterone (timed), DHEA-S
  • Men: baseline PSA (and set up reflex percent-free PSA)

• Step 2: Correct the fundamentals

• • Vitamin D, thyroid, sleep, nutrition, movement, stress/ANS
  • Begin gut-directed care: fiber, probiotic, reduction of trigger foods, bowel regularity

• Step 3: Address insulin resistance

• • Metformin titration to 2000 mg/day as tolerated or GLP-1/GIP agonists
  • Track waist circumference, fasting insulin, and A1c

• Step 4: Treat androgen-related symptoms in PCOS

• • Spironolactone with monitoring; counsel on timeline
  • For fertility goals: add progesterone support and carefully coordinate with cycle timing

• Step 5: Layer hormones thoughtfully

• • Testosterone carefully dosed in PCOS-like phenotypes; “start low, go slow.”
  • Reassess SHBG, free and total T, and symptoms
  • In persistent low mood/libido: evaluate and optimize DHEA-S

• Step 6: Ongoing monitoring

• • Re-lab at intervals based on therapy; anchor to symptoms and function
  • For men: use percent-free PSA and MRI where appropriate to reduce unnecessary biopsies

Why This Integrative Model Works

• Systems thinking: We treat nodes in the same web—gut, insulin, inflammation, autonomic balance—that modulate hormone action.
• Receptor-centric approach: We enhance the cell’s capacity to respond—via thyroid optimization, vitamin D, sleep, and fitness—rather than only pushing more hormone.
• Safety and personalization: Slow titration and objective monitoring translate into fewer side effects and higher adherence.
• Durability: By addressing root drivers (dysbiosis, insulin resistance, ANS imbalance), improvements persist and the risk of relapse declines.

Final Takeaways

• Do not chase lower SHBG to “free up” testosterone; improve insulin sensitivity, dose hormones prudently, and protect SHBG’s metabolic value.
• Treat PCOS from the gut outward, using metformin or GLP-1/GIP support, anti-androgens for symptoms, and hormonal support tailored to fertility goals.
• Use percent-free PSA and MRI to improve prostate risk stratification in men on testosterone.
• Optimize DHEA-S as a neurosteroid and immunomodulator, particularly in patients with persistent low mood/libido despite basic optimization.
• Integrative chiropractic care—targeting structure, movement, and autonomic balance—potentiates endocrine therapies and accelerates recovery.

In my practice and in the work of colleagues across functional and integrative medicine, these strategies consistently transform outcomes. Hormones do not act in isolation; when we align the body’s systems, the results speak for themselves.

References

• Ahmed, H. U., El-Shater BosailymultiparametricC., et al. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet, 389(10071), 815–822.
• American Urological Association. (2018, updated). Evaluation and management of testosterone deficiency.
• American Urological Association. (2023). Early detection of prostate cancer guideline.
• Biondi, B. (2019). Mechanisms in endocrinology: Heart failure and thyroid dysfunction. European Journal of Endocrinology, 180(5), R211–R221.
• Brown, J., Farquhar, C., Lee, O., Toomath, R., & Jepson, R. G. (2009). Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database of Systematic Reviews, (2), CD000194.
• Catalona, W. J., Southwick, P. C., Slawin, K. M., et al. (1998). Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology, 52(2), 255–260.
• Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews, 33(6), 981–1030.
• Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2009). Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 295(11), 1288–1299.
• Jensterle, M., Kravos, N. A., Pfeifer, M., et al. (2015). A randomized study comparing liraglutide with metformin for weight loss in women with PCOS. Human Reproduction, 30(9), 2188–2196.
• Labrie, F. (2015). Intracrinology. Molecular and Cellular Endocrinology, 408, 177–187.
• Labrie, F., Bélanger, A., Cusan, L., et al. (2005). Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. Journal of Clinical Endocrinology & Metabolism, 80(3), 660–666.
• Lerchbaum, E., & Obermayer-Pietsch, B. (2012). Vitamin D and fertility: a systematic review. European Journal of Endocrinology, 166(5), 765–778.
• Lord, J. M., Flight, I. H., & Norman, R. J. (2003). Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ, 327(7421), 951–953.
• Pilz, S., Tomaschitz, A., Ritz, E., & Pieber, T. R. (2011). Vitamin D status and arterial hypertension: a systematic review. Nature Reviews Cardiology, 6(10), 621–630.
• Qi, X., Yun, C., Sun, L., & Xia, J. (2022). Gut microbiota and PCOS: where we are and where we are going. Reproductive Biology and Endocrinology, 20, 173.
• Rath, S., Heidrich, B., Pieper, D. H., & Vital, M. (2022). Probiotics in metabolic disorders and PCOS: current evidence and future directions. Microbiome, 10, 11.
• Rosner, W., Hryb, D. J., Khan, M. S., Nakhla, A. M., & Romas, N. A. (2007). Sex hormone-binding globulin: anatomy and physiology of a new regulatory system. Journal of Steroid Biochemistry and Molecular Biology, 102(1–5), 241–247.
• Simo, R., Saez-Lopez, C., Barbosa-Desongles, A., Hernandez, C., & Selva, D. M. (2012). Novel insights into SHBG regulation and clinical implications. Trends in Endocrinology & Metabolism, 26(7), 376–383.
• Thompson, I. M., Goodman, P. J., Tangen, C. M., et al. (2006). The influence of finasteride on prostate cancer. NEJM, 349(3), 215–224.
• Traish, A. M., Kang, H. P., Saad, F., & Guay, A. T. (2011). Dehydroepiandrosterone (DHEA) is a steroid precursor and an active hormone in human physiology. Journal of Sexual Medicine, 8(11), 2960–2982.

For more about my approach and clinical insights, visit:

• https://dralexjimenez.com/
• https://www.linkedin.com/in/dralexjimenez/

SEO tags: PCOS treatment, SHBG and testosterone, integrative chiropractic care, DHEA benefits, percent-free PSA, prostate MRI, metformin titration, GLP-1 for PCOS, spironolactone hirsutism, thyroid optimization, vitamin D hormone receptors, insulin resistance and hormones, functional medicine hormones, testosterone therapy safety, gut dysbiosis PCOS